Alaunos Therapeutics (TCRT) Competitors $3.25 -0.13 (-3.85%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.30 +0.06 (+1.69%) As of 07/16/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. OKUR, KZR, BDRX, ESLA, MAAQ, OVID, SNYR, MRNS, ALLK, and COEPShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include OnKure Therapeutics (OKUR), Kezar Life Sciences (KZR), Biodexa Pharmaceuticals (BDRX), Estrella Immunopharma (ESLA), Mana Capital Acquisition (MAAQ), Ovid Therapeutics (OVID), Synergy CHC (SNYR), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors OnKure Therapeutics Kezar Life Sciences Biodexa Pharmaceuticals Estrella Immunopharma Mana Capital Acquisition Ovid Therapeutics Synergy CHC Marinus Pharmaceuticals Allakos Coeptis Therapeutics OnKure Therapeutics (NASDAQ:OKUR) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has more risk & volatility, OKUR or TCRT? OnKure Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.79, suggesting that its stock price is 179% less volatile than the S&P 500. Which has stronger valuation & earnings, OKUR or TCRT? Alaunos Therapeutics has higher revenue and earnings than OnKure Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.47Alaunos Therapeutics$10K533.00-$4.68M-$2.54-1.28 Do analysts rate OKUR or TCRT? OnKure Therapeutics currently has a consensus price target of $32.33, indicating a potential upside of 1,198.53%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer OKUR or TCRT? In the previous week, OnKure Therapeutics had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.89 beat OnKure Therapeutics' score of 1.87 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment OnKure Therapeutics Very Positive Alaunos Therapeutics Very Positive Do institutionals & insiders believe in OKUR or TCRT? 91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is OKUR or TCRT more profitable? OnKure Therapeutics' return on equity of -49.13% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -49.13% -45.72% Alaunos Therapeutics N/A -169.34%-124.28% SummaryOnKure Therapeutics beats Alaunos Therapeutics on 10 of the 15 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.54M$2.41B$5.51B$9.31BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-1.289.1828.1219.69Price / Sales533.00755.11439.46100.25Price / CashN/A160.6835.5357.53Price / Book2.524.698.235.67Net Income-$4.68M$30.99M$3.23B$257.51M7 Day Performance-34.08%-0.20%-0.52%-0.16%1 Month Performance-11.20%8.67%6.71%9.89%1 Year Performance-47.57%-4.17%27.10%15.08% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.5957 of 5 stars$3.25-3.8%N/A-47.1%$5.54M$10K-1.2840Positive NewsGap DownOKUROnKure Therapeutics3.5331 of 5 stars$2.46+2.9%$32.33+1,214.4%N/A$33.24MN/A-0.47N/ANews CoverageKZRKezar Life Sciences4.1435 of 5 stars$4.53-0.4%$39.50+772.0%-30.8%$33.11M$7M-0.4260News CoverageAnalyst ForecastBDRXBiodexa Pharmaceuticals0.2139 of 5 stars$0.87+0.6%N/AN/A$31.83M$470K0.0020Gap DownESLAEstrella Immunopharma3.1268 of 5 stars$0.87-1.2%$16.00+1,736.1%-42.1%$31.52MN/A-3.35N/AMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+657.3%$30.88MN/A0.001OVIDOvid Therapeutics4.6386 of 5 stars$0.43+15.0%$3.13+626.7%-62.5%$30.58M$570K-1.2360Positive NewsGap DownHigh Trading VolumeSNYRSynergy CHC3.9172 of 5 stars$3.30-2.1%$10.00+203.0%N/A$30.33M$34.83M0.0040Gap DownMRNSMarinus Pharmaceuticals2.0364 of 5 stars$0.55-0.2%$3.92+613.3%-62.8%$30.32M$30.99M-0.22110ALLKAllakos3.3279 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190COEPCoeptis Therapeutics0.5051 of 5 stars$8.28+7.1%N/A+61.6%$29.10M$62.87K-1.432News Coverage Related Companies and Tools Related Companies OnKure Therapeutics Alternatives Kezar Life Sciences Alternatives Biodexa Pharmaceuticals Alternatives Estrella Immunopharma Alternatives Mana Capital Acquisition Alternatives Ovid Therapeutics Alternatives Synergy CHC Alternatives Marinus Pharmaceuticals Alternatives Allakos Alternatives Coeptis Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRT Stock Alerts